April 8, 2008 - SCN has signed a world‐wide license agreement for the patent rights to the obesity related virus adenovirus 36 (AD36). The agreement is signed between SCN and the internationally renowned researcher and Professor Richard L. Atkinson. In conjunction with the agreement, SCN has initiated additional research cooperation with Karolinska Institutet in Stockholm, one of Europe’s leading medical universities, and Professor Atkinson. SCN aims for a commercial launch of its first diagnostic tests within six to twelve months.
Professor Atkinson comments; “The results from a number of research projects indicate that between 30 and 57 percent of obese people and as much as 18 percent of lean people could be infected by the human adenovirus AD36.” Results from animal testing show that nearly all individuals infected by the virus had significantly more fat compared with a control group of lean animals, even though their food intake was in fact less... [PDF] Scandinavian Clinical Nutrition's press Release -
Blog Archive
-
▼
2008
(55)
-
▼
April
(9)
- Orexigen Therapeutics : Completion of Enrollment ...
- Znomics : Drug Discovery Program in Obesity Using ...
- Pacific Biometrics : Research Contracts as Part of...
- University of Virginia : DiaKine's Lisofylline Red...
- SCN, Scandinavian Clinical Nutrition : diagnosis a...
- Memory Pharmaceuticals : Advance Development and C...
- Genaera Corporation : MSI-1436 Data Presented at S...
- Merck : Phase III Data Showed Taranabant, its Inv...
- VIVUS : Enrollment in Phase 3 EQUIP (OB-302) Tria
-
▼
April
(9)